These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20657013)

  • 21. Expression profile and overexpression outcome indicate a role for βKlotho in skeletal muscle fibro/adipogenesis.
    Phelps M; Stuelsatz P; Yablonka-Reuveni Z
    FEBS J; 2016 May; 283(9):1653-68. PubMed ID: 26881702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N; Shull AY; Teng Y
    Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
    Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
    FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
    Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
    Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 29. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
    Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
    Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
    Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.
    Turunen SP; von Nandelstadh P; Öhman T; Gucciardo E; Seashore-Ludlow B; Martins B; Rantanen V; Li H; Höpfner K; Östling P; Varjosalo M; Lehti K
    Cell Death Differ; 2019 Dec; 26(12):2577-2593. PubMed ID: 30903103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action.
    Zhang J; Gupte J; Gong Y; Weiszmann J; Zhang Y; Lee KJ; Richards WG; Li Y
    EBioMedicine; 2017 Feb; 15():173-183. PubMed ID: 28041926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.
    Drafahl KA; McAndrew CW; Meyer AN; Haas M; Donoghue DJ
    PLoS One; 2010 Dec; 5(12):e14412. PubMed ID: 21203561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway.
    Ye X; Guo Y; Zhang Q; Chen W; Hua X; Liu W; Yang Y; Chen G
    PLoS One; 2013; 8(1):e55615. PubMed ID: 23383245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF19-
    Raja A; Park I; Haq F; Ahn SM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different roles of N- and C- termini in the functional activity of FGF21.
    Micanovic R; Raches DW; Dunbar JD; Driver DA; Bina HA; Dickinson CD; Kharitonenkov A
    J Cell Physiol; 2009 May; 219(2):227-34. PubMed ID: 19117008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease.
    Chen Q; Jiang Y; An Y; Zhao N; Zhao Y; Yu C
    Biochem Biophys Res Commun; 2011 Jun; 409(4):651-6. PubMed ID: 21616061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.